Related Experiment Videos
Antihypertensive therapy with isradipine in patients with special safety concerns
1Hahnemann University, Philadelphia, Pennsylvania.
Insights
Isradipine (ISR), a calcium channel blocker, effectively controls hypertension in complex patients. ISR demonstrates an excellent safety profile with minimal adverse effects and no negative impact on renal function or glycemic control.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hypertension management in complicated patients necessitates careful consideration of age, comorbidities, organ function, and drug interactions.
- Antihypertensive agents must possess a proven safety profile for this patient population.
Purpose of the Study:
- To evaluate the safety and efficacy of monotherapy with isradipine (ISR), a calcium channel blocker (CCB), in treating hypertension in complicated patients.
- To assess the effects of ISR on renal function, cardiac parameters, and metabolic control.
Main Methods:
- Clinical trials involving monotherapy with isradipine (ISR) at recommended therapeutic dosages.
- Assessment of blood pressure control, cardiac function (heart rate, conduction, contractility), renal function (renal plasma flow, vascular resistance, GFR, filtration fraction), and metabolic parameters (glycemic control, lipid metabolism).
- Evaluation of adverse event profiles and drug interactions with commonly used medications in elderly patients.
Main Results:
- ISR effectively controlled blood pressure with an excellent safety profile.
- No significant adverse effects on heart rate, cardiac conduction, or contractility were observed.
- ISR improved renal function by increasing renal plasma flow and decreasing renal vascular resistance without compromising glomerular filtration rate.
- ISR demonstrated long-term natriuretic effects and did not negatively impact glycemic control or lipid metabolism.
- Common adverse effects were mild and transient, primarily related to vasodilation (headache, dizziness, edema).
- No adverse interactions were reported with digoxin, nitroglycerin, oral hypoglycemics, and hydrochlorothiazide.
Conclusions:
- Isradipine (ISR) is a safe and effective first-line antihypertensive agent for complicated patients.
- ISR offers benefits including improved renal hemodynamics and a favorable safety profile, making it suitable for elderly patients and those with comorbidities.
- The lack of adverse metabolic effects and drug interactions further supports ISR's utility in complex hypertensive individuals.
Abstract:
Treatment of hypertension in the complicated patient requires a specialized approach focusing on the treatment of the blood pressure and concurrent medical problems. Therapy must be chosen in consideration of the patient's age, multiple illnesses, declining organ function, and possible drug interactions. This requires that the antihypertensive agent chosen have a demonstrated safe profile. In clinical trials, monotherapy with the calcium channel blocker (CCB) isradipine (ISR) at a recommended therapeutic dosage has controlled blood pressure with an excellent level of safety. In these studies, ISR had no significant effect on heart rate, cardiac conduction, or cardiac contractility and no negative effect on renal function. In hypertensive patients with both normal and impaired renal function, ISR significantly increased renal plasma flow while decreasing renal vascular resistance without decreasing glomerular filtration rate and filtration fraction. ISR has long-term natriuretic effects that may provide additional benefits in antihypertensive therapy. Most adverse effects associated with ISR are mild, transient, and related to vasodilation. The most frequently reported adverse reactions are headache, dizziness, and edema. ISR does not affect glycemic control or lipid metabolism in either diabetic or nondiabetic patients. It has no reported adverse interaction with some of the most commonly used medications for elderly patients, including digoxin, nitroglycerin, oral hypoglycemics, and hydrochlorothiazide. ISR may be used as a first-line agent for the treatment of hypertension in complicated patients.